• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TrialAdvance launches group to target underrepresented populations in clinical trials

TrialAdvance launches group to target underrepresented populations in clinical trials

March 8, 2012
CenterWatch Staff

TrialAdvance has created a new strategy group called iDICT (Improving Disparities In Clinical Trials), aimed at helping study sponsors achieve the federal government’s directive to increase participation of underrepresented populations in clinical trials.

“Despite the fact that the government issued its strongest recommendations yet about the need to address participation of minorities, women, seniors and other underrepresented populations in clinical trials, few companies have been able to comply,” said Kathleen B. Drennan, president and CEO of TrialAdvance. “Many have not yet incorporated this effort into their protocol development and up-front planning process, leading to inadequate enrollment of these challenging populations.

Rebecca Budd will serve as the group’s managing director and chief strategist. “Rebecca Budd’s insight has been developed from years of experience in research and analytics, medical communication and patient recruitment strategy, and she has been successful in developing effective strategies for reaching these difficult-to-enroll subgroups,” said Drennan.

“The motivation to participate in clinical trials differs from subgroup to subgroup,” said Budd. “TrialAdvance’s programs not only help sponsor teams achieve better study participant demographics, but also complement Engagement-Training, our proprietary program designed to help study sites tap into their diverse patient communities.”

Budd works with multicultural experts to develop and execute study strategies targeting underrepresented populations. Previously, she worked for Iris Global Clinical Trial Solutions, the Omnicom Group and Hoffmann-LaRoche. Her range of therapeutic experience includes cardiovascular, endocrinology, virology and neurology. 

“There is significant pressure for companies to improve clinical trial participation of women, children, the elderly and diverse racial and ethnic groups today,” said Budd. “These populations bear a disproportionate burden of many diseases. It is critical for clinical trial sponsors to explore differences in how a disease progresses and how patients respond to treatment. The creation of the iDICT Group solidifies TrialAdvance’s commitment to bring clinical trials to all people.”

TrialAdvance builds Super Sites, high-performing clinical trial investigative sites that perform better, recruit patients faster and complete trials sooner, all key to avoiding study delays.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing